Law Offices of Marc S. Henzel Commences Investigations of Fifth Street Finance Corp., Amicus Therapeutics, Inc., 6D Global Technologies, Inc., BofI Holdings, Inc., Zafgen, Inc., and Valeant Pharmaceuticals, Inc.

News provided by

Nov 02, 2015, 09:28 ET

MERION STATION, Pa., Nov. 2, 2015 /PRNewswire/ --

The Law Office is investigating Fifth Street Finance Corp. (FSC) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On February 9, 2015, the Company reported its fiscal results for the fourth quarter of 2014 and revealed that although total assets had increased, the net investment income had actually decreased. On this news, the price fell from $8.49 to $7.22 (a decline of $1.27).

If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at [email protected], or visit the firms website at www.henzellaw.com.

Amicus Therapeutics, Inc. (FOLD)

The Law Office is investigating Amicus Therapeutics, Inc. (FOLD) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On September 15, 2015, the Company announced that it had received positive news from the Food and Drug Administration regarding one of its drug candidates. On October 2, 2015, the Company stated that the FDA news was in fact not positive. On this news, the stock price fell from $13.75 to $6.39 (a decline of $7.36).

6D Global Technologies, Inc. (SIXD)

The Law Office is investigating 6D Global Technologies, Inc. (SIXD)

concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. According to a complaint filed, the defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) the Company had deficient internal controls, (2) the lack of internal controls allowed Defendant Benjamin Wei to exert influence and control over the Company, (3) the Company was engaged in improper and undisclosed material related party transactions, (4) Defendants were engaged in a scheme to manipulate the Company's stock price, and (5) as a result, the Company's public statements were materially false and misleading and/or lacked a reasonable basis at all relevant times.

BofI Holding, Inc. (BOFI)

The Law Office is investigating BofI Holding, Inc. (BOFI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. According to a complaint filed, the Company made false and/or misleading statements and/or failed to disclose that: (1) BofI's internal controls were frequently disregarded; (2) BofI's borrowers included foreign nationals who should have been off-limits under federal anti-money-laundering laws; (3) many BofI accounts lacked required tax identification numbers; and (4) BofI fired an internal auditor who raised these issues to management and to federal regulators.

Zafgen, Inc. (ZFGN)

The Law Office is investigating Zafgen, Inc. (ZFGN) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On October 12, 2015, the stock price dropped following heavy insider selling. Then, on October 16, 2015, the stock fell to $10.36, following the Company's confirmation of a patient death and news that the FDA had imposed a clinical hold on the Company's drug.

Valeant Pharmaceuticals International, Inc. (VRX)

The Law Office is investigating Valeant Pharmaceuticals International, Inc. concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. According to a complaint filed, defendants made false and misleading statements and/or failed to disclose adverse information about the Company's business and prospects, including that the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs, that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks, and that without the use of the specialty pharmacies, Valeant's financial performance and Class Period financial guidance would have been negatively impacted.

The Law Offices of Marc S. Henzel is a national shareholder litigation firm representing shareholders & investors in various areas of securities laws including but not limited to; class actions, derivatives, transactional (buyouts/mergers/acquisitions) and FINRA & NYSE Arbitrations.

Attorney advertising. © 2015 Law Offices of Marc S. Henzel. The law firm responsible for this advertisement is Marc S. Henzel. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Law Offices of Marc S. Henzel
Marc S. Henzel
Email: [email protected]
Phone 610-660-8000
Website: www.henzellaw.com.

SOURCE Law Offices of Marc S. Henzel